Ono Pharmaceutical Co., Ltd. (OPHLY)
4.799
-0.04
(-0.85%)
USD |
OTCM |
Oct 02, 16:00
Ono Pharmaceutical Enterprise Value : 6.161B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 6.161B |
| October 01, 2026 | 6.219B |
| September 30, 2026 | 6.360B |
| September 29, 2026 | 6.614B |
| September 28, 2026 | 6.882B |
| September 25, 2026 | 6.712B |
| September 24, 2026 | 6.642B |
| September 23, 2026 | 6.825B |
| September 22, 2026 | 7.008B |
| September 21, 2026 | 6.656B |
| September 18, 2026 | 6.557B |
| September 17, 2026 | 6.585B |
| September 16, 2026 | 6.318B |
| September 15, 2026 | 6.445B |
| September 14, 2026 | 6.461B |
| September 11, 2026 | 6.445B |
| September 10, 2026 | 6.388B |
| September 09, 2026 | 6.487B |
| September 08, 2026 | 6.684B |
| September 04, 2026 | 6.684B |
| September 03, 2026 | 6.867B |
| September 02, 2026 | 6.659B |
| September 01, 2026 | 6.628B |
| August 31, 2026 | 6.501B |
| August 28, 2026 | 6.543B |
| Date | Value |
|---|---|
| August 27, 2026 | 6.554B |
| August 26, 2026 | 6.647B |
| August 25, 2026 | 6.600B |
| August 24, 2026 | 6.571B |
| August 21, 2026 | 6.600B |
| August 20, 2026 | 6.656B |
| August 19, 2026 | 6.698B |
| August 18, 2026 | 6.543B |
| August 17, 2026 | 6.416B |
| August 14, 2026 | 6.440B |
| August 13, 2026 | 6.459B |
| August 12, 2026 | 6.473B |
| August 11, 2026 | 6.466B |
| August 10, 2026 | 6.289B |
| August 07, 2026 | 6.446B |
| August 06, 2026 | 6.261B |
| August 05, 2026 | 6.195B |
| August 04, 2026 | 6.367B |
| August 03, 2026 | 6.320B |
| July 31, 2026 | 6.483B |
| July 30, 2026 | 6.557B |
| July 29, 2026 | 6.442B |
| July 28, 2026 | 6.289B |
| July 27, 2026 | 6.360B |
| July 24, 2026 | 6.346B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 84.01B |
| Daiichi Sankyo Co., Ltd. | 30.79B |
| Astellas Pharma, Inc. | 27.81B |
| Eisai Co., Ltd. | 8.332B |
| Chugai Pharmaceutical Co., Ltd. | 56.97B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 151.63M |
| Revenue (Quarterly) | 728.94M |
| Total Expenses (Quarterly) | 577.39M |
| EPS Diluted (Quarterly) | 0.1075 |
| Gross Profit Margin (Quarterly) | 75.31% |
| Profit Margin (Quarterly) | 20.80% |
| Earnings Yield | 7.33% |